DHS Fund Adjusts Stock Weights, Leaning on AbbVie, Altria, and Merck
What happened
The WisdomTree U.S. High Dividend Fund (DHS) adjusted its stock weightings, leaning on AbbVie, Merck, and Altria among its 326 holdings. The fund has paid monthly distributions, resulting in a trailing yield of 3.2% through November 10, 2026. Separately, the SEC legally requires fiduciaries to prioritize client interests.
From aol.com
Why it matters
DHS weights its stocks based on projected dividend dollars, adjusting for value, quality, and momentum. However, the fund's heavy exposure to drugmakers and tobacco means its dividend payouts could be vulnerable to cuts. The SEC's rule reinforces the legal obligation of fiduciaries to clients.
From aol.com
Who's involved
- DHSManages the U.S. High Dividend Fund, which adjusts portfolio weights based on dividend projections.
- AbbVieIs one of the pharmaceutical stocks DHS is leaning on for its weighting strategy.
- AltriaIs one of the tobacco stocks DHS is leaning on for its weighting strategy.
- MerckIs one of the pharmaceutical stocks DHS is leaning on for its weighting strategy.
- SECLegally requires fiduciaries to place client interests first.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie might see increased investment flow due to the fund's higher stock weighting.
- AltriaSpeculative
Altria might see increased investment flow due to the fund's higher stock weighting.
- MerckSpeculative
Merck might see increased investment flow due to the fund's higher stock weighting.